Loading, please wait....jpg)
.jpg)
The Premier June 17, 2025 CE webinar will be held from 12 - 1 pm EDT. We are pleased to provide one (1) 60-minute knowledge-based, ACPE-accredited CE activity to pharmacists and pharmacy technicians.
Incorporating Anti-Amyloid-β (Aβ) Monoclonal Antibody Therapies into Alzheimer’s Disease Management
SPEAKER: Marketa Marvanova, PharmD, PhD, BCGP, BCPP, FASCP, Dean and Professor, Pacific University School of Pharmacy, Hillboro, OR
ACPE Universal Activity Number: 0122-0000-25-012-L01-P [0.1 CEU] [1 Contact Hr.]
Date: Jun 17, 2025 12:00 PM - 01:00 PM
Fee
$0.00
CE Hours
1.00
CE Units
0.100
Registration closes on Jun 17, 2025 12:10 PM
Activity Type
- Knowledge
Target Audience(s)
- Pharmacists
Accreditation(s)
|
Premier, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
|
Requirements for CE Credit
CE participation will be provided to CPE Monitor within 45 days of the CE activity upon CE registration, confirmation of participation for the entire activity, and completion of online learning assessment questions and speaker evaluation administered post-session.
Support/Credits
Premier, Inc. has received no outside support for the administration of this program.
Objectives
- Discuss currently available pharmacologic treatments for Alzheimer’s disease
- Explain the role and place in therapy of FDA-approved anti-amyloid-B monoclonal antibodies in the treatment paradigm for Alzheimer’s disease
- Identify patient characteristics and clinical indicators to appropriately select candidates for anti-amyloid-B monoclonal antibody therapy
- Review the risks, benefits, and administration protocols of FDA-approved anti-amyloid-B monoclonal antibodies to facilitate informed decision
Speaker(s)/Author(s)
|
Marketa Marvanova, PharmD, PhD, BCGP, BCPP, FASCP
|
Activity Number
0122-0000-25-012-L01-P
Date:
06/17/25
Time:
12:00 PM - 01:00 PM
CE Hours
1.00